Trials / Completed
CompletedNCT00507793
Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus
An Open-Label Study to Evaluate the Efficacy and Safety of Cyclosporine Reduction in de Novo Renal Allograft Recipients Receiving Sirolimus: a Dose Comparative Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 385 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of different doses of cyclosporine given concomitantly with a fixed dose of sirolimus in kidney transplant recipients.
Detailed description
To evaluate the safety and efficacy of different doses of cyclosporine given concomitantly with a fixed dose of sirolimus in kidney transplant recipients. Cyclosporine blood levels, graft rejection rates and renal function will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sirolimus | |
| DRUG | Cyclosporine |
Timeline
- Start date
- 2000-04-01
- Completion
- 2002-06-01
- First posted
- 2007-07-27
- Last updated
- 2007-07-27
Source: ClinicalTrials.gov record NCT00507793. Inclusion in this directory is not an endorsement.